The Anti-Fibrotic Effect of GV1001 Combined With Gemcitabine on Treatment of Pancreatic Ductal Adenocarcinoma

Oncotarget - United States
doi 10.18632/oncotarget.12057
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Outcomes of Gemcitabine Treatment for Invasive Ductal Pancreatic Cancer

Suizo
2007English

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts

Frontiers in Oncology
Cancer ResearchOncology
2019English

The BET Inhibitor I-Bet762 Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances the Therapeutic Effect of Gemcitabine

Scientific Reports
Multidisciplinary
2018English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

Front Cover: A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma (ChemMedChem 15/2019)

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2019English

Correction: Inhibition of HIF-1α By PX-478 Enhances the Anti-Tumor Effect of Gemcitabine by Inducing Immunogenic Cell Death in Pancreatic Ductal Adenocarcinoma

Oncotarget
Oncology
2019English

Tumoral EHF Predicts the Efficacy of Anti-Pd1 Therapy in Pancreatic Ductal Adenocarcinoma

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Nationwide Trends in Incidence, Treatment and Survival of Pancreatic Ductal Adenocarcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

Development and in Vitro Characterization of a Gemcitabine-Loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma

Anticancer Research
MedicineCancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy